Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children,
with survival rates lagging well behind those observed at initial diagnosis. Although there …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

Background Bacteremia and other invasive bacterial infections are common among children
with cancer receiving intensive chemotherapy and in pediatric recipients of hematopoietic …

Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents,
are essential as evolving resistance patterns are considered, additional treatment …

Paediatric patients with cancer and those undergoing haematopoietic cell transplantation
are at high risk of bacterial infections. The 8th European Conference on Infections in …

Abstract Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) have
continued to lag behind outcomes reported for children with acute lymphoblastic leukemia …

Background Myeloma causes profound immunodeficiency and recurrent, serious infections.
Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of …

Specific protocols define eligibility, conditioning, donor selection, graft composition and
prophylaxis of graft vs. host disease for children and young adults undergoing hematopoietic …

Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial damage
syndrome that is increasingly identified as a complication of both autologous and allogeneic …